Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ: MNMD )

7.125 -0.985 (-12.15%)
Streaming Delayed Price Updated: 12:50 PM EST, Jan 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Why Mind Medicine Stock Is Soaring Today
Via The Motley Fool
MindMed to Be Added to the Nasdaq Biotechnology Index
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress
From Mind Medicine
Via Business Wire
Psychedelics Company MindMed Prices Public Offering Aiming To Raise $75M
Via Benzinga
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
From Mind Medicine Inc.
Via Business Wire
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy
From Mind Medicine Inc.
Via Business Wire
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
Is Your Mind Ready to Consider Investing in Psychedelics Stocks?
Don't jump in without doing some research first. 
Via The Motley Fool
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
From Mind Medicine (MindMed) Inc.
Via Business Wire
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental health care. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
MindMed to Participate in Upcoming Investor Conferences
From Mind Medicine Inc.
Via Business Wire
MindMed Reports Third Quarter 2024 Financial Results and Business Updates
From Mind Medicine Inc.
Via Business Wire
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update
From Mind Medicine Inc.
Via Business Wire
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come. 
Via Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are... 
Via Talk Markets
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a... 
Via Talk Markets
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
MindMed to Participate in September Investor Conferences
From Mind Medicine Inc.
Via Business Wire
Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week
Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past... 
Via Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD
This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest... 
Via Talk Markets
MNMD Stock Earnings: Mind Medicine Misses EPS for Q2 2024
MNMD stock results show that Mind Medicine missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
MindMed Reports Second Quarter 2024 Financial Results and Business Updates
From Mind Medicine Inc.
Via Business Wire
Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering
From Mind Medicine (MindMed) Inc.
Via Business Wire
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference
From Mind Medicine Inc.
Via Business Wire
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update
From Mind Medicine Inc.
Via Business Wire
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy. 
Via Benzinga
MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer
From Mind Medicine Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.